# Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

> **NCT06099093** · PHASE4 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Castration-resistant Prostate Carcinoma

## Interventions

- **DRUG:** 18F-DCFPyl

## Key facts

- **NCT ID:** NCT06099093
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06099093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06099093, "Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06099093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*